Compare Canopy Growth Corp (CGC) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Canopy Growth Corp vs Procter & Gamble Co — how do they compare? Canopy Growth Corp trades at $0.96 (market cap $398.46M), while Procter & Gamble Co trades at $147.71 (market cap $340.16B). The key difference: Procter & Gamble Co is far larger — about 853.7× Canopy Growth Corp's market cap, and Procter & Gamble Co pays a 2.92% dividend while Canopy Growth Corp pays none. Which is the better fit depends on your goals.
| CGC | PG | |
|---|---|---|
Market Cap | $398.46M | $340.16B |
Sector | Health | Consumer Staples |
52-Week High | $1.92 | $167.18 |
52-Week Low | $0.86 | $138.10 |
Enterprise Value | $337.90M | $365.64B |
Volume | — | 6,423,436 |
Dividend Yield | — | 2.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Canopy Growth (CGC) trades at $0.96, down 1.15% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported a net loss of $598.12 million in 2025, with revenue declining to $269 million, though recent quarterly earnings showed one beat and two misses against expectations. Cash flow remains negative, but the balance sheet shows improving debt-to-asset ratios, down to 33.13% in 2025 from 53.61% in 2023.
The outlook is cautious; while cost-cutting and restructuring efforts are underway, profitability remains elusive, and the stock faces risks including potential delisting due to low share price. Analyst sentiment is divided, with 33% recommending buy, 41% hold, and 26% sell. Investors should weigh the potential for a turnaround against significant operational and regulatory challenges in the cannabis sector.
Procter & Gamble (PG) trades at $147.43, down 0.63% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS expected at $1.42. Revenue for 2025 reached $84.28 billion, with a net income margin of 19.16%, while valuation ratios like P/E of 21.36 and P/S of 4.09 reflect a premium to peers. Recent news highlights PG's dividend reliability and supply chain improvements.
The outlook for PG is mixed, with strong fundamentals and a 53.85% analyst buy rating supporting upside to a $161.71 consensus target, but risks include premium valuation concerns and soft demand. Investment appeal lies in its stable cash flow and 69-year dividend growth streak, though near-term volatility may persist due to economic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Canopy Growth Corp
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
